Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408977 | 0.82 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4410497 | 0.82 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4410208 | 0.82 | RAB9A (0.43) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 | |
| SCHEMBL4410550 | 0.77 | ALOX5 (0.49) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 | |
| SCHEMBL1386431 | 0.74 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 | |
| SCHEMBL2931650 | 0.73 | CCNC (0.44) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 | |
| SCHEMBL4408770 | 0.72 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12EGFR | |
| SCHEMBL4415373 | 0.71 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12EGFR | |
| SCHEMBL2929529 | 0.70 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 | |
| SCHEMBL1386715 | 0.69 | MAPK14 (0.43) | MAPK14MAPK11MAPK13MAPK12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | claimed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.